XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Debt - Liability for Sale of Future Royalties (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
Beginning balance $ 1,814,097
Less: Non-cash royalty revenue payable to Royalty Pharma (73,349)
Plus: non-cash interest expense recognized 102,340
Cash received from Royalty Pharma 241,792
Ending balance $ 2,084,880
Effective interest rate of the liability component 9.90%